natgillin/translations-raw huggingface dataset:
Rekovelle was compared with GONAL-f (follitropin alfa), another fertility medicine, in one study involving 1,326 women who were undergoing controlled ovarian stimulation for IVF or ICSI. 
Zdravilo Rekovelle so primerjali z zdravilom GONAL-f (folitropin alfa), tj. drugim zdravilom za zdravljenje neplodnosti, v študiji, ki je vključevala 1 326 žensk v postopku nadzorovane stimulacije jajčnikov za IVF ali ICSI.
Rekovelle must not be used in women with tumours of the pituitary gland or hypothalamus, or cancer of the breast, womb or ovary. 
Zdravilo Rekovelle se ne sme uporabljati pri ženskah s tumorji na hipofizi ali hipotalamusu, z rakom dojk, maternice ali jajčnikov.
OHSS is when a woman's ovaries over-respond to stimulation, causing symptoms such as vomiting, diarrhoea and pain. 
Sindrom hiperstimulacije jajčnikov se pojavi, kadar se ženska čezmerno odzove na stimulacijo, povzroča pa simptome, kot so bruhanje, driska in bolečina.
Rekovelle is available as a solution for injection, contained in a cartridge to be used with Rekovelle injection pen. 
Zdravilo Rekovelle je na voljo v obliki raztopine za injiciranje v vložku, ki se uporablja skupaj z injekcijskim peresnikom Rekovelle.
The active substance in Rekovelle, follitropin delta, is a copy of the natural hormone called folliclestimulating hormone (FSH) which plays a key role in fertility in women by stimulating the production of eggs in the ovaries. 
Zdravilna učinkovina v zdravilu Rekovelle, folitropin delta, je imitacija naravnega hormona, imenovanega folikle stimulirajoči hormon (FSH), ki ima zaradi spodbujanja nastajanja jajčec v jajčnikih glavno vlogo pri ženski plodnosti.
Giving extra stimulation with Rekovelle helps increase the number of eggs produced in the ovaries, which means that more eggs can then be collected and fertilised in the laboratory. 
Z dodatno stimulacijo s pomočjo zdravila Rekovelle se poveča število jajčec, ki nastanejo v jajčnikih, kar pomeni, da se lahko odvzame in v laboratoriju oplodi več jajčec.
It is used to stimulate the ovaries to produce several eggs at the time, which can then be collected and fertilised in the laboratory. 
Uporablja se za spodbujanje jajčnikov, da v njih nastane več jajčec hkrati, ki jih nato odvzamejo in oplodijo v laboratoriju.
Rekovelle must not be used when there is enlargement of an ovary or a cyst that is caused by something other than polycystic ovarian syndrome, or when there is unexplained bleeding from the vagina. 
Zdravilo Rekovelle se ne sme uporabljati, če imate povečane jajčnike ali ciste, ki niso posledica sindroma policističnih jajčnikov, ali imate krvavitve iz nožnice brez znanega vzroka.
For the full list of all side effects reported with Rekovelle, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rekovelle, glejte navodilo za uporabo.
Rekovelle contains the active substance follitropin delta. 
Zdravilo Rekovelle vsebuje zdravilno učinkovino folitropin delta.
The CHMP considered that Rekovelle was effective in obtaining several eggs at the same time following stimulation in women undergoing fertility treatment. 
Odbor CHMP je menil, da je zdravilo Rekovelle pri ženskah, ki se zdravijo zaradi neplodnosti, učinkovito pri pridobivanju več jajčec hkrati po stimulaciji.
Rekovelle is a medicine given to women who are having fertility treatments such as in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). 
Rekovelle je zdravilo, ki se daje ženskam, ki se zdravijo zaradi neplodnosti, na primer z zunajtelesno oploditvijo jajčne celice (IVF) ali neposrednim vnosom semenčice v citoplazmo jajčne celice (ICSI).
How does Rekovelle work? 
Kako zdravilo Rekovelle deluje?
The application was withdrawn at ‘day 120'. 
Družba je vlogo umaknila na „120.
The summary of the opinion of the Committee for Orphan Medicinal Products for Tekinex can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/Rare disease designations. 
Povzetek mnenja Odbora za zdravila sirote za zdravilo Tekinex je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Tekinex was not compared directly with any other treatment. 
Zdravila Tekinex niso neposredno primerjali z nobeno drugo vrsto zdravljenja.
The CHMP also had concerns about the doses used in the study and the criteria used for measuring the medicine's effectiveness. 
CHMP je imel tudi zadržke glede odmerkov, ki so jih uporabili v študiji, in meril, uporabljenih za merjenje učinkovitosti zdravila.
The effects of Tekinex were first tested in experimental models before being studied in humans. 
Učinki zdravila Tekinex so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
This means that the CHMP had evaluated the initial documentation provided by the company and formulated a list of questions. 
dan.“ To pomeni, da je CHMP ocenil začetno dokumentacijo, ki jo je predložila, in sestavil seznam vprašanj.
The company had not yet responded to the questions at the time of the withdrawal. 
Ob umiku vloge družba še ni odgovorila na vprašanja.
The study looked at how the patients responded to treatment based on results of blood tests taken to measure how active the cancer was. 
V študiji so ugotavljali, kako se bolniki odzivajo na zdravljenje, in sicer na podlagi preiskav krvi, s katerimi so izmerili aktivnost raka.
Because the number of patients with CML is low, the disease is considered ‘rare', and Tekinex was designated an ‘orphan medicine' (a medicine used in rare diseases) on 2 September 2004. 
Ker je bolnikov s KML malo, se bolezen šteje za „redko“ in zdravilo Tekinex je bilo dne 2. septembra 2004 določeno kot „zdravilo sirota“ (zdravilo, ki se uporablja za redke bolezni).
It was to be available as a powder to be made up into a solution for injection. 
Na voljo naj bi bilo kot prašek za pripravo raztopine za injiciranje.
Finally, following an inspection of the study sites, the Committee noted that there were some inconsistencies in the application that could have affected the reliability of the study results. 
Po pregledu mest študije pa je Odbor ugotovil nekaj neskladnosti v vlogi, ki bi lahko vplivale na zanesljivost rezultatov študije.
The company informed the CHMP that clinical trials with Tekinex will continue. 
Družba je obvestila CHMP, da se bodo klinična preskušanja z zdravilom Tekinex nadaljevala.
Tekinex is a medicine that contains the active substance omacetaxine mepesuccinate. 
Tekinex je zdravilo, ki vsebuje zdravilno učinkovino omacetaksin mepesukcinat.
Based on the review of the data, at the time of the withdrawal the CHMP had some concerns and was of the provisional opinion that Tekinex could not have been approved. 
Na podlagi pregleda podatkov v času umika vloge je imel CHMP nekaj zadržkov in bil začasnega mnenja, da zdravila Tekinex ni mogoče odobriti.
The CHMP was of the view that the medicine's benefits were uncertain. 
CHMP je menil, da koristi zdravila niso jasne.
There was also insufficient follow-up of the patients following treatment and the Committee was doubtful about the medicine being safe enough to be self-administered by patients as intended by the company. 
Odbor je imel pomisleke, ali je varnost zdravila zadostna, da bi si ga bolniki dajali sami, kot je nameravala družba.
The active substance in Tekinex, omacetaxine, is an inhibitor of protein synthesis. 
Zdravilna učinkovina v zdravilu Tekinex, omacetaksin, je zaviralec nastajanja beljakovin.
What is Tekinex? 
Kaj je zdravilo Tekinex?
The way it works is unclear, but it is thought to disrupt the production of the Bcr-Abl tyrosine kinase enzyme. 
Način njegovega delovanja ni jasen, vendar naj bi prekinil nastajanje encima tirozin-kinaze BCR-ABL.
On 11 January 2011, ChemGenex Europe SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Tekinex intended to be used to treat patients with Philadelphia chromosome-positive chronic myeloid leukaemia who have the ‘Bcr-Abl T315I kinase domain' mutation and whose previous treatment with imatinib had failed. 
Družba ChemGenex Europe SAS je dne 11. januarja 2011 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Tekinex, namenjenim zdravljenju bolnikov s kronično mieloično levkemijo, pozitivno na kromosom Philadelphia, ki imajo mutacijo „T315I domene kinaze BCR-ABL“ in pri katerih je bilo predhodno zdravljenje z imatinibom neuspešno.
The company presented results from a main study involving 66 patients with Philadelphia-positive CML and the T315I mutation, whose previous treatment with imatinib had failed. 
Družba je predložila rezultate glavne študije, v katero je bilo vključenih 66 bolnikov s KML, pozitivno na kromosom Philadelphia, in mutacijo T315I, pri katerih je bilo predhodno zdravljenje z imatinibom neuspešno.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Tekinex did not outweigh its risks. 
Zato je CHMP v času umika menil, da koristi zdravila Tekinex ne odtehtajo z njim povezanih tveganj.
Tekinex was therefore expected to work in Ph+ patients with the T315I mutation. 
Zato so za zdravilo Tekinex pričakovali, da bo delovalo pri bolnikih s Ph+ z mutacijo T315I.
What was Tekinex expected to be used for? 
Za kaj naj bi se zdravilo Tekinex uporabljalo?
Ph+ means that some of the patient's genes have rearranged themselves to form a special chromosome called the Philadelphia chromosome which produces an enzyme, Bcr-Abl kinase that leads to the development of leukaemia. 
Ph+ pomeni, da so se določeni geni bolnika prerazporedili tako, da je nastal poseben kromosom, imenovan kromosom Philadelphia, ki tvori encim, kinazo BCR-ABL, ki povzroči razvoj levkemije.
It was to be used in patients whose previous treatment with imatinib (another anticancer medicine) had failed, possibly due to a mutation in the gene for the Bcr-Abl kinase called the ‘T315I mutation'. 
Zdravilo naj bi se uporabljalo pri bolnikih, pri katerih je bilo predhodno zdravljenje z imatinibom (drugim zdravilom proti raku) neuspešno, verjetno zaradi mutacije gena za kinazo BCR-ABL, imenovane „mutacija T315I.“
It is derived from harringtonine, a substance extracted from a Chinese evergreen. 
Izdelan je iz haringtonina, snovi, pridobljene iz aglaoneme.
Tekinex was expected to be used to treat adults with ‘Philadelphia chromosome positive' (Ph+) chronic myeloid leukaemia (CML, a cancer of a type of white blood cells called granulocytes). 
Zdravilo Tekinex naj bi se uporabljalo za zdravljenje odraslih bolnikov s kronično mieloično levkemijo (KML, rak vrste belih krvnih celic, imenovanih granulociti), „pozitivno na kromosom Philadelphia“ (Ph+).
How is Tekinex expected to work? 
Kako naj bi zdravilo Tekinex delovalo?
The T315I mutation changes certain properties of the enzyme, making it harder for these medicines to attach to it. Because omacetaxine does not act in this way, its action is not affected by the T315I mutation. 
Ker omacetaksin ne deluje na ta način, mutacija T315I ne vpliva na njegovo delovanje.
Other medicines known as tyrosine kinase inhibitors, including imatinib, act in CML by attaching directly to the Bcr-Abl tyrosine kinase enzyme. 
Druga zdravila, ki spadajo v skupino zaviralcev tirozin-kinaze, vključno z imatinibom, pri KML delujejo tako, da se vežejo neposredno na encim tirozin-kinaza BCR-ABL. Mutacija T315I spremeni določene lastnosti encima, kar oteži vezavo teh zdravil nanj.
1 Commission Regulation (EC) NO 1177/2006 of 1 August 2006 implementing Regulation (EC) No 2160/2003 of the European Parliament and of the Council as regards requirements for the use of specific control methods in the framework of the national programmes for the control of Salmonella in poultry (OJ L 212, 2.8.2006, p.3).http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:212:0003:0005:EN:PDF 
1 Uredba Komisije (ES) št. 1177/2006 z dne 1. avgusta 2006 o izvajanju Uredbe (ES) št. 2160/2003 Evropskega parlamenta in Sveta glede zahtev za uporabo posebnih metod nadzora v okviru nacionalnih programov za nadzor salmonele pri perutnini (UL L 212, 2.8.2006, str. 3) - http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:212:0003:0005:SL:PDF
Member state/EEA 
Država članica/ EGP
Laboratoires Biové 3 rue de Lorraine 62510 Arques FRANCE 
Laboratoires Biové 3 rue de Lorraine 62510 Arques FRANCIJA
Carabela La Niña nº 12 5ª planta 08017 Barcelona SPAIN 
Carabela La Niña nº 12 5ª planta 08017 Barcelona ŠPANIJA
With regard to established withdrawal periods they ranged in the Member States from 1 to 9 days. 
Uveljavljene karence so v državah članicah znašale od 1 do 9 dni.
• the CVMP considered the overall submitted data and the general knowledge on the substance resulting from its well-established used in veterinary medicines for over 20 years. 
• CVMP je upošteval vse predložene podatke in splošno vedenje o snovi, ki je bilo zbrano na podlagi dobro uveljavljene uporabe v veterinarski medicini več kot 20 let.
CVMP Note for guidance: Approach towards harmonisation of withdrawal periods http://www.emea.europa.eu/pdfs/vet/swp/003695en.pdf 
Navodilo CVMP: pristop k usklajevanju karenc http://www.emea.europa.eu/pdfs/vet/swp/003695en.pdf
It was noted that some parts of the data presented were identical but were submitted by different Applicants/Marketing Authorisation Holders. 
Ugotovljeno je bilo tudi, da so bili določeni deli predloženih podatkov enaki, čeprav so jih predložili različni predlagatelji/imetniki dovoljenja za promet z zdravilom.
For some of the products concerned a treatment period of 5 to 7 days was recommended which was considered too long with respect to the aim of achieving an optimal balance between bacteriological cure rate and risk for resistance development. 
Za nekaj zadevnih zdravil je bilo priporočeno obdobje zdravljenja 5 do 7 dni, kar se šteje za predolgo glede na cilj doseganja optimalnega ravnovesja med stopnjo bakteriološke ozdravitve in tveganjem pojava odpornosti.
As regards to antimicrobial resistance against colistin it should be noted that firm conclusions regarding antimicrobial resistance could not be reached in the absence of consumption data. 
V zvezi s protimikrobno odpornostjo proti kolistinu je treba omeniti, da trdnih zaključkov v zvezi s protimikrobino odpornostjo ni mogoče doseči, če ni podatkov o porabi.
The procedure involved 47 veterinary medicinal products authorised or pending authorisation in different Member States of the European Union (see Annex I). 
Postopek je zajel 47 zdravil za uporabo v veterinarski medicini, ki so že odobrena ali v postopku odobritve v državah članicah Evropske unije (glejte Dodatek I).
The duration of treatment currently recommended in the products authorised for calves and lambs was mainly 3 days. 
Trajanje zdravljenja, ki je trenutno priporočeno za zdravila, odobrena za teleta in jagnjeta, je v glavnem 3 dni.
The only area of potential risks identified was the risk of lack of efficacy in case of invasive strains and the possibility of interference with Salmonella control programs. 
Edino odkrito področje možnega tveganja je bilo tveganje neučinkovitosti v primeru invazivnih sevov ter možnosti interference s programi za nadzor salmonele.
This dose was the recommended dose for the majority of the products included in this referral and has thus been in clinical use for many years. 
Ta odmerek je bil priporočen za večino zdravil, ki so vključena v to napotitev, kar pomeni, da so bila v klinični rabi več let.
7100 Vejle 
7100 Vejle DANSKA
The data packages submitted consist of bibliographic data, available in the public domain, and proprietary data. 
Predloženi sklopi podatkov obsegajo bibliografske podatke, ki so javno dostopni, in pravno zaščitene podatke.
Colistin sulfate is a polypeptide antibiotic belonging to the polymyxins group of antibiotics. 
Kolistinijev sulfat je polipeptidni antibiotik iz skupine polimiksinov.
Applicant/ Marketing Authorisation Holder 
Predlagatelj/ imetnik dovoljenja za promet z zdravilom
The data submitted to the Committee for evaluation was of poor quality and in some cases lacking to substantiate the claims, doses, duration of treatment or withdrawal periods. 
Podatki, predloženi Odboru v oceno, so bili slabe kakovosti in v določenih primerih niso utemeljevali trditev, odmerkov, trajanj zdravljenja in karenc.
CENAVISA, S.A. Camí Pedra Estela S/N 
Romunija CENAVISA, S.A. Camí Pedra Estela S/N
Oltenita ROMANIA 
Oltenita ROMUNIJA
The submitted data by the Applicants/Marketing Authorisation Holders showed that the concerned veterinary medicinal products are authorised or pending authorisations via different marketing authorisation procedures (mutual recognition procedures or national procedures) and under various legal bases (full and generic). 
Podatki, ki so jih predložili predlagatelji/imetniki dovoljenja za promet z zdravilom, so pokazali, da so zadevna zdravila za uporabo v veterinarski medicini odobrena ali v postopku odobritve po različnih postopkih (postopki z medsebojnim priznavanjem ali nacionalni postopki) in na različnih pravnih podlagah (popolnih, generičnih).
Consequently, the use of colistin for the treatment of infections caused by Salmonella may interfere with specific control methods and national programmes for the control of Salmonella; 
Posledično lahko uporaba kolistina za zdravljenje okužb, ki jih povzročijo salmonele, ovira specifične metode za nadzor in nacionalne programe za nadzor salmonel;
CEVA SANTE ANIMALE ROMANIA SRL 
Romunija CEVA SANTE ANIMALE ROMANIA SRL
There was no documented evidence indicating an increase in the development of resistance relevant to human or animal health. 
Ni dokumentiranih dokazov, ki bi kazali povečanja pojavnosti odpornosti, ki bi bila pomembna za zdravje ljudi ali živali.
INN Strength Pharmaceutical form 
Jakost Farmacevts ka oblika
Furthermore, the Committee noted that treatment of subclinical Salmonella with the objective to reduce the number of bacteria might interfere with control programmes for this disease1. 
Poleg tega je Odbor ugotovil, da zdravljenje subkliničnih okužb s salmonelo s ciljem zmanjšanja števila bakterij morda posega v programe za nadzor te bolezni1.
Two products had a recommended duration of treatment of 3-4 consecutive days. 
Dve zdravili imata priporočeno trajanje zdravljenja 3-4 zaporedne dni.
Zone Industrielle des Touches 200, avenue de Mayenne 
Romunija Sogeval Zone Industrielle des Touches 200, avenue de Mayenne
The presented clinical data for treatment of salmonelosis in chickens was not conclusive and the appropriateness of using this substance for treating Salmonella infections could be questioned. 
Predstavljeni klinični podatki o zdravljenju salmoneloze pri piščancih niso dali jasnih zaključkov, zato je primernost uporabe te snovi za zdravljenje okužb s salmonelo vprašljiva.
Due to the poor absorption in the gut colistin would only be effective against noninvasive Salmonella. 
Kolistin bi bil zaradi slabe absorpcije v prebavilih učinkovit le proti neinvazivnim salmonelam.
Ceva Animal Health Slovakia, spol. 
Slovaška Ceva Animal Health Slovakia, spol.
The recommended daily dose should be divided into two if the product is to be administered directly into the mouth of the animal. 
Priporočeni dnevni odmerek je treba razdeliti v dva dela, če se zdravilo daje neposredno v gobec živali.
With regard to the efficacy in chickens a study report from public literature was provided where E. coli infections were treated with colistin sulfate given in feed. 
V zvezi z učinkovitostjo pri piščancih je bilo predloženo poročilo o študiji iz javne literature, v kateri so okužbe z E. coli zdravili s kolistinijevim sulfatom, ki so ga dajali v krmo.
With regard to the duration of treatment of gastrointestinal infections caused by non-invasive E. coli in the target species it was noted that the treatment effect is easily monitored and thus treatment duration can be adjusted according to the course of the disease. 
V zvezi s trajanjem zdravljenja okužb prebavil, ki jih povzročajo neinvazivni sevi E. coli pri ciljnih živalskih vrstah, je bilo ugotovljeno, da se učinek zdravljenja enostavno spremlja, zato se lahko trajanje zdravljenja prilagaja glede na potek bolezni.
LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE VETERINARY MEDICINAL PRODUCTS, ANIMAL SPECIES, ROUTE OF ADMINISTRATION, WITHDRAWAL PERIOD AND APPLICANTS/MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVIL ZA UPORABO V VETERINARSKI MEDICINI, ŽIVALSKIH VRST, POTI UPORABE, KARENC IN PREDLAGATELJEV/IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
In addition it was noted that the recommended daily dose for calves, lambs and pigs should be divided into two if the product is to be administered directly into the mouth of the animal. 
Poleg tega je bilo ugotovljeno, da je treba priporočeni dnevni odmerek za teleta, jagnjeta in prašiče razdeliti v dva dela, če se zdravilo daje neposredno v gobec živali.
This said, it was agreed that the suggested dose of 50 000 IU per kg body weight twice daily was reasonable. 
Glede na to je bilo dogovorjeno, da je predlagani odmerek 50 000 i.e. na kg telesne mase dvakrat dnevno razumen.
With regard to the duration of treatment, considering the fact that treatment effect is easily monitored and thus treatment duration can be adjusted according to the course of the disease the Committee agreed to recommend a harmonised duration of treatment of 3-5 days for all products intended for calves and lambs. 
Odbor je v zvezi s trajanjem zdravljenja upošteval, da je učinek zdravljenja mogoče enostavno spremljati in se lahko trajanje zdravljenja prilagaja glede na potek bolezni, in se je zato strinjal s priporočilom usklajenega trajanja zdravljenja 3-5 dni za vsa zdravila, ki so namenjena teletom in jagnjetom.
S.C. CRIDA PHARM S.R.L. 
Romunija S.C. CRIDA PHARM S.R.L.
It was noted that the analysis, based on the determination of colistin sulfate concentration in the gastrointestinal tract after different levels of exposure and minimum inhibitory concentrations (MIC) data from E. coli strains collected in five European countries could be questioned as the surrogate endpoint Cmax/MIC was not validated for local exposure in the gastrointestinal tract and the fraction of active compound bound to the faecal content was not known. 
Ugotovljeno je bilo, da je analiza na podlagi določevanja koncentracij kolistinijevega sulfata v prebavilih po različnih ravneh izpostavitve in podatkov o najnižji inhibicijski koncentraciji (MIK) za seve E. coli, zbranih v petih evropskih državah, vprašljiva, saj nadomestno merilo izida Cmax/MIK ni bilo potrjeno glede lokalne izpostavljenosti v prebavilih, zato delež zdravilne učinkovine, ki je vezana na feces, ni znan.
With regard to the efficacy in pigs the pre-clinical data revealed that the selection of dose rate and dose interval for colistin sulfate in pigs was chosen by using a pharmacokinetic/pharmacodynamic (PK/PD) analysis. 
V zvezi z učinkovitostjo pri prašičih so predklinični podatki pokazali, da sta bila hitrost odmerjanja in presledek med odmerki za kolistinijev sulfat pri prašičih izbrana z analizo farmakokinetike/farmakodinamike.
In the submitted Periodic Safety Update Reports no lack of efficacy has been reported for the claimed indications in calves and lambs. 
V predloženih rednih posodobljenih poročilih o varnosti zdravil niso poročali o neučinkovitosti za predlagane indikacije pri teletih in jagnjetih.
For some of the products concerned the recommended treatment interval was 3 to 5 days. 
Za nekatera zadevna zdravila je bil priporočeno trajanje zdravljenja 3 do 5 dni.
It was noted that no data were submitted by the Applicants/Marketing Authorisation Holders to support the establishment of optimal duration of treatment for colibacilosis in calves and lambs. 
Ugotovljeno je bilo, da predlagatelji/imetniki dovoljenja za promet z zdravilom niso predložili podatkov v podporo določitvi optimalnega trajanja zdravljenja kolibaciloze pri teletih in jagnjetih.